Cyclic Nucleotide Phosphodiesterases, Type 3
"Cyclic Nucleotide Phosphodiesterases, Type 3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cyclic nucleotide phosphodiesterase subfamily that is inhibited by the binding of CYCLIC GMP to an allosteric domain found on the enzyme and through phosphorylation by regulatory kinases such as PROTEIN KINASE A and PROTEIN KINASE B. The two members of this family are referred to as type 3A, and type 3B, and are each product of a distinct gene. In addition multiple enzyme variants of each subtype can be produced due to multiple alternative mRNA splicing.
| Descriptor ID |
D054684
|
| MeSH Number(s) |
D08.811.277.352.640.150.300 D12.644.360.008.300 D12.776.476.008.300
|
| Concept/Terms |
Cyclic Nucleotide Phosphodiesterases, Type 3- Cyclic Nucleotide Phosphodiesterases, Type 3
- cGMP-Inhibited Cyclic Nucleotide Phosphodiesterase
- cGMP Inhibited Cyclic Nucleotide Phosphodiesterase
- Cyclic Nucleotide Phosphodiesterase PDE3 Family
- Phosphodiesterase III
- cGMP-Inhibited Phosphodiesterase
- Phosphodiesterase, cGMP-Inhibited
- cGMP Inhibited Phosphodiesterase
|
Below are MeSH descriptors whose meaning is more general than "Cyclic Nucleotide Phosphodiesterases, Type 3".
Below are MeSH descriptors whose meaning is more specific than "Cyclic Nucleotide Phosphodiesterases, Type 3".
This graph shows the total number of publications written about "Cyclic Nucleotide Phosphodiesterases, Type 3" by people in this website by year, and whether "Cyclic Nucleotide Phosphodiesterases, Type 3" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 3 | 3 |
| 2007 | 0 | 2 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclic Nucleotide Phosphodiesterases, Type 3" by people in Profiles.
-
Cyclic nucleotide phosphodiesterase 3A1 protects the heart against ischemia-reperfusion injury. J Mol Cell Cardiol. 2013 Nov; 64:11-9.
-
Identification of novel mutations confirms PDE4D as a major gene causing acrodysostosis. Hum Mutat. 2013 Jan; 34(1):97-102.
-
Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat. 2011 Aug; 128(3):783-94.
-
Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart. Circ Res. 2007 Mar 02; 100(4):489-501.
-
Activation of extracellular signal-regulated kinase 5 reduces cardiac apoptosis and dysfunction via inhibition of a phosphodiesterase 3A/inducible cAMP early repressor feedback loop. Circ Res. 2007 Mar 02; 100(4):510-9.
-
Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell. 2005 Oct 07; 123(1):25-35.
-
A positive feedback loop of phosphodiesterase 3 (PDE3) and inducible cAMP early repressor (ICER) leads to cardiomyocyte apoptosis. Proc Natl Acad Sci U S A. 2005 Oct 11; 102(41):14771-6.
-
Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure. Circulation. 2005 May 17; 111(19):2469-2476.
-
Role of phosphodiesterase 3 in NO/cGMP-mediated antiinflammatory effects in vascular smooth muscle cells. Circ Res. 2003 Sep 05; 93(5):406-13.
-
Milrinone echocardiographic viability test: a pilot study. J Am Soc Echocardiogr. 2001 Jul; 14(7):668-75.